Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Empathogen

or [[:Category:Mood_stabilizers|Mood stabilizer]]

Use the filters below to narrow your results.

4-FA (1) · 5-APB (1) · 5-MAPB (1) · 6-APB (1) · 6-APDB (1) · Agomelatine (1) · Amoxapine (1) · Butylone (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Ephylone (1) · Ethylone (1) · Imipramine (1) · Isocarboxazid (1) · Levomilnacipran (1) · Maprotiline (1) · MDA (1) · MDAI (1) · MDEA (1) · MDMA (1) · Mephedrone (1) · Methylone (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Olanzapine / Fluoxetine (1) · Phenelzine (1) · PMA (1) · PMMA (1) · Protriptyline (1) · Reboxetine (1) · Sertraline (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1) · Valproate (valproic acid, divalproex sodium, sodium valproate) (1)

None (17) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Depakote, Depakote ER, Depakene, Depacon (IV) (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Symbyax (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

Irreversible non-selective MAO inhibitor (3) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000975-QINU`"' Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks'"`UNIQ--ref-00000976-QINU`"'. (1) · '"`UNIQ--vote-00001549-QINU`"' Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard'"`UNIQ--ref-0000154A-QINU`"'. (1)

None (34) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"' (1) · '"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"' (1)

None (34) · 25 mg (1) · 6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability (1) · Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate (1)

None (34) · 125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine (1)

None (34) · 18 mg olanzapine / 75 mg fluoxetine per day (1) · 200 mg/d (1) · 60 mg/kg/d (typically up to 3000 mg/d) (1)

None (33) · IV (1) · Oral (4) · rectal (off-label use of injection) (1)

None (33) · Anticonvulsant effect within days; mood-stabilizing effect 1-3 weeks (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood improvement at 1-3 weeks; full effect 4-6 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (33) · 12 hours (IR); 24 hours (ER) (1) · 24 hours (1) · Chronic daily dosing (1) · Long (1)

None (33) · 9-16 hours'"`UNIQ--ref-0000097C-QINU`"' (1) · Olanzapine ~30 hours; fluoxetine 1-4 days (norfluoxetine 7-15 days)'"`UNIQ--ref-0000154D-QINU`"' (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (33) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"' (1) · ~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"' (1) · ~50% (highly variable) (1)

None (33) · '''Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk''' (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist'"`UNIQ--ref-0000097E-QINU`"' (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (33) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for hepatotoxicity (especially children <2 with metabolic disorders), teratogenicity, and pancreatitis'"`UNIQ--ref-0000097F-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)